Herceptin founder snags $158M for his UCLA-biotech partnership TORL BioTherapeutics

Kyle LaHucik

Senior Reporter

One of the key researchers behind identifying HER2 as a breast cancer target — and turning that discovery into what became the blockbuster Herceptin — has formed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Herceptin founder snags $158M for his UCLA-biotech partnership TORL BioTherapeutics

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Isomorphic Labs gets $600M from Thrive, GV and Alphabet

FDA's Peter Marks resigns, says he won't accept Kennedy's 'misinformation and lies'

Vertex’s second-generation diabetes cell therapy fails early-stage study

Bluebird gets new M&A bid, seeking to top private equity offer

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Her­ceptin founder snags $158M for his UCLA-biotech part­ner­ship TORL Bio­Ther­a­peu­tics

Senior Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Herceptin founder snags $158M for his UCLA-biotech partnership TORL BioTherapeutics